Compare BioNano Genomics Inc (BNGO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Match Group Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Match Group Inc trades at $36.5 (market cap $8.45B). The key difference: Match Group Inc is far larger — about 618.6× BioNano Genomics Inc's market cap, and Match Group Inc pays a 2.17% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MTCH | |
|---|---|---|
Market Cap | $13.66M | $8.45B |
Sector | Health | Media |
52-Week High | $4.92 | $41.24 |
52-Week Low | $1.06 | $28.90 |
Enterprise Value | $16.26M | $11.42B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
MTCH trades at $36.73, down 1.42% amid mixed technical signals and recent earnings volatility. The stock shows bearish momentum with key support at $35, while fundamentals reveal strong profitability with 74.8% gross margins and 20.17% net income margin. Recent Q2 2026 earnings missed revenue estimates despite Tinder engagement improvements, creating investor uncertainty about near-term growth.
MTCH presents a value opportunity with attractive P/E of 13.05 and analyst consensus target of $42.33 (15% upside), but faces execution risks in Tinder's turnaround and high debt load. The 53% buy rating reflects optimism for Hinge growth and margin expansion, though quarterly volatility requires careful monitoring of user trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
